January 23, 2012

HELIX BIOPHARMA CORP. RESPONDS TO DISSIDENT PROXY CIRCULAR IN CONNECTION WITH THE JANUARY 30, 2012 SHAREHOLDER MEETING (PDF)

AURORA, Ontario, January 23, 2012 – Helix BioPharma Corp. (“Helix” or the “Company”), (TSX, NYSE Amex, FSE: HBP) today announced that it has responded to the proxy material (the “Dissident Circular”) that has been filed by a group of dissident shareholders (the “Dissident Group”) which is being led by Andreas Kandziora, a minority shareholder and a former agent of the Company, and Zbigniew Lobacz, an insider of the Company who owns approximately 10% of Helix’s issued and outstanding shares.